ClinicalTrials.gg
CompletedNCT05015361Updated Aug 20, 2021

A Trial of Efficacy and Safety of Remimazolam Tosilate for Injection in Local Anesthesia Assisted Sedation

A Phase 2 interventional study of Remimazolam Tosilate and Propofol Injection. in Local Anesthesia Assisted Sedation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-08-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2021, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of Remimazolam Tosilate for injection in local anesthesia assisted sedation, and to explore the dose range of remazolam toluenesulfonate for injection in local anesthesia assisted sedation.

02

Conditions studied

  • Local Anesthesia Assisted Sedation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring local anesthesia assisted sedation
  3. Male or female
  4. Meet the weight standard
  5. Conform to the ASA Physical Status Classification

Exclusion criteria

Exclusion Criteria:

  1. Previous respiratory or pulmonary diseases
  2. Subjects who had received general anesthesia
  3. Subjects with a history of myocardial infarction or unstable angina pectoris
  4. Subjects with atrioventricular block or cardiac insufficiency
  5. Subjects with a history of ischemic stroke or
  6. Subjects with poor blood pressure control after medication
  7. Subjects with abnormal clotting function
  8. Subjects with a history of mental illness and a history of cognitive impairment epilepsy
  9. Subjects with a history or possibility of a difficult airway
  10. Subject with a history of substance abuse and drug abuse
  11. Abnormal values in the laboratory
  12. Allergic to a drug ingredient or component
  13. Pregnant or nursing women
  14. No during the specified period of time
  15. Participated in clinical trials of other drugs (received experimental drugs)
  16. The inestigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Treatment group A/B

    Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate

    Drug: Remimazolam Tosilate

  • Active comparator
    Treatment group C

    Treatment group C: Propofol Injection.

    Drug: Propofol Injection.

Interventions

  • Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose

  • DrugPropofol Injection.

    Treatment group C: Propofol Injection.

06

What researchers measure

Primary outcomes

  1. The time to maintain target sedation as a percentage of the total study administration time.

    Time frame: through study completion,an average of about 1 hour

Secondary outcomes

  1. Proportion of subjects who achieved target sedation within 3 minutes after starting intravenous injection of load dose test drugs;

    Time frame: 3 minutes after administration

  2. Proportion of subjects receiving remedial sedation;

    Time frame: through study completion,an average of about 1 hour

  3. The time from the start of intravenous injection of load dose test drug to the first achievement of target sedation;

    Time frame: Time to achieve target sedation, an average of about 4 minutes

  4. The time from stopping infusion of test drugs to reaching MOAA/S level 5 for the first time after operation

    Time frame: Recovery time, an average of about 7 minutes

  5. Anesthesiologists' satisfaction with sedation

    Time frame: through study completion,an average of about 1 hour

  6. Evaluation of subjects' satisfaction with sedation treatment;

    Time frame: through study completion,an average of about 1 hour

  7. Incidence of anterograde amnesia.

    Time frame: through study completion,an average of about 1 hour

07

Study locations

1 site
  • West China Hospital
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jun 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2021
First posted
Aug 20, 2021
StartActual
May 7, 2021
Primary completionActual
Jun 18, 2021
CompletionActual
Jul 4, 2021
Last update
Aug 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05015361
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
May 7, 2021
Primary completion
Jun 18, 2021
Completion
Jul 4, 2021
Last update
Aug 20, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion